In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...
For men with elevated prostate-specific antigen (PSA) levels who are at average risk for prostate cancer, evaluating suspicious lesions with MRI-directed targeted biopsy instead of systematic biopsy ...
Management of low-risk prostate cancer in a population-based cohort of Australian men between 2008 and 2016. This is an ASCO Meeting Abstract from the 2019 Genitourinary Cancers Symposium. This ...
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Findings address a gap of knowledge highlighted in current guidelines on the use of MRI in the diagnosis and management of prostate cancer. (HealthDay News) — Men with negative multiparametric ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
The MarketWatch News Department was not involved in the creation of this content. GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", ...
Grade group 1 prostate cancer assessment should include PSA, stage, and disease volume for accurate risk evaluation. Active surveillance is safe for most low-risk patients, but higher-risk features ...
Population-based screening showed that men over age 50 with PSA of 3 ng per milliliter or higher and negative MRI results could safely forgo biopsy. Detection of clinically significant cancer among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results